Identification of a highly conserved surface on tat variants

Journal of Biological Chemistry

Volumn 288, Issue 26, 2013, Pages 19072-19080

  Mediouni, Sonia ^a   Darque, Albert ^a   Ravaux, Isabelle ^a   Baillat, Gilbert ^a   Devaux, Christian ^b   Loret, Erwann P ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b University of Montpellier I and II   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL TREATMENTS; CIRCULAR DICHROISM SPECTRA; DISULFIDE BRIDGE; EXTRACELLULAR; NEUTRALIZING ANTIBODIES;

COVALENT BONDS; VACCINES;

ANTIBODIES;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7G12; PEPTIDE VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ARTICLE; BETA TURN; BINDING COMPETITION; CIRCULAR DICHROISM; CONTROLLED STUDY; DISULFIDE BOND; DRUG DESIGN; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS TYPING;

CELLULAR IMMUNE RESPONSE; EPITOPE MAPPING; HIV-1; PROTEIN DESIGN; TAT; VACCINE; VACCINE DEVELOPMENT;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING SITES; BINDING, COMPETITIVE; CIRCULAR DICHROISM; COMPUTATIONAL BIOLOGY; CONSERVED SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HELA CELLS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MODELS, MOLECULAR; PEPTIDES; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, WISTAR; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; RATTUS;

EID: 84879564272     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.466011     Document Type: Article

References (45)

1. Campbell, G. R., and Loret, E. P. (2009) What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology 6, 50-61
2. Wong-Staal, F., and Gallo, R. C. (1985) Human T-lymphotropic retroviruses. Nature 317, 395-403
3. Debaisieux, S., Rayne, F., Yezid, H., and Beaumelle, B. (2012) The ins and outs of HIV-1 Tat. Traffic 13, 355-363
4. Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debatin, K. M., and Krammer, P. H. (1995) Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375, 497-500
5. Mediouni, S., Darque, A., Baillat, G., Ravaux, I., Dhiver, C., Tissot-Dupont, H., Mokhtari, M., Moreau, H., Tamalet, C., Brunet, C., Paul, P., Dignat-George, F., Stein, A., Brouqui, P., Spector, S. A., Campbell, G. R., and Loret, E. P. (2012a) Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect. Disord. Drug Targets 12, 81-86
6. Campbell, G. R., Senkaali, D., Watkins, J., Esquieu, D., Opi, S., Yirrell, D. L., Kaleebu, P., and Loret, E. P. (2007) Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine 25, 8441-8447 (Pubitemid 350148112)
7. Senkaali, D., Kebba, A., Shafer, L. A., Campbell, G. R., Loret, E. P., Van Der Paal, L., Grosskurth, H., Yirrell, D., and Kaleebu, P. (2008) Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans. AIDS Res. Hum. Retroviruses 24, 587-594 (Pubitemid 351571034)
8. Loret, E. P., Georgel, P., Johnson, W. C., Jr., and Ho, P. S. (1992) Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator. Proc. Natl. Acad. Sci. U.S.A. 89, 9734-9738
9. Koken, S. E., Greijer, A. E., Verhoef, K., van Wamel, J., Bukrinskaya, A. G., and Berkhout, B. (1994) Intracellular analysis of in vitro modified HIV Tat protein. J. Biol. Chem. 269, 8366-8375 (Pubitemid 24200255)
10. Bayer, P., Kraft, M., Ejchart, A., Westendorp, M., Frank, R., and Rösch, P. (1995) Structural studies of HIV-1 Tat protein. J. Mol. Biol. 247, 529-535
11. 13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. C. R. Acad. Sci. III 323, 883-894
12. 1H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein. Biopolymers 62, 324-335
13. 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant. Retrovirology 5, 83
14. Tahirov, T. H., Babayeva, N. D., Varzavand, K., Cooper, J. J., Sedore, S. C., and Price, D. H. (2010) Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 465, 747-751
15. Shojania, S., and O'Neil, J. D. (2006) HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy. J. Biol. Chem. 281, 8347-8356 (Pubitemid 43847935)
16. Serrière, J., Dugua, J. M., Bossus, M., Verrier, B., Haser, R., Gouet, P., and Guillon, C. (2011) Fab-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by x-ray crystallography. J. Mol. Biol. 405, 33-42
17. Mediouni, S., Baillat, G., Darque, A., Ravaux, I., and Loret, E. (2011) HIV-1 infected patients have antibodies recognizing folded Tat. Infect. Disord. Drug Targets 11, 57-63
18. Caselli, E., Betti, M., Grossi, M. P., Balboni, P. G., Rossi, C., Boarini, C., Cafaro, A., Barbanti-Brodano, G., Ensoli, B., and Caputo, A. (1999) DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J. Immunol. 162, 5631-5638 (Pubitemid 29307178)
19. Ensoli, B., Fiorelli, V., Ensoli, F., Lazzarin, A., Visintini, R., Narciso, P., Di Carlo, A., Monini, P., Magnani, M., and Garaci, E. (2008) The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 22, 2207-2209
20. Longo, O., Tripiciano, A., Fiorelli, V., Bellino, S., Scoglio, A., Collacchi, B., Alvarez, M. J., Francavilla, V., Arancio, A., Paniccia, G., Lazzarin, A., Tambussi, G., Din, C. T., Visintini, R., Narciso, P., Antinori, A., D'Offizi, G., Giulianelli, M., Carta, M., Di Carlo, A., Palamara, G., Giuliani, M., Laguardia, M. E., Monini, P., Magnani, M., Ensoli, F., and Ensoli, B. (2009) Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 27, 3306-3312
21. Ensoli, B., Fiorelli, V., Ensoli, F., Lazzarin, A., Visintini, R., Narciso, P., Di Carlo, A., Tripiciano, A., Longo, O., Bellino, S., Francavilla, V., Paniccia, G., Arancio, A., Scoglio, A., Collacchi, B., Ruiz Alvarez, M. J., Tambussi, G., Tassan Din, C., Palamara, G., Latini, A., Antinori, A., D'Offizi, G., Giuliani, M., Giulianelli, M., Carta, M., Monini, P., Magnani, M., and Garaci, E. (2009) The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 28, 371-378
22. Ensoli, B., Bellino, S., Tripiciano, A., Longo, O., Francavilla, V., Marcotullio, S., Cafaro, A., Picconi, O., Paniccia, G., Scoglio, A., Arancio, A., Ariola, C., Ruiz Alvarez, M. J., Campagna, M., Scaramuzzi, D., Iori, C., Esposito, R., Mussini, C., Ghinelli, F., Sighinolfi, L., Palamara, G., Latini, A., Angarano, G., Ladisa, N., Soscia, F., Mercurio, V. S., Lazzarin, A., Tambussi, G., Visintini, R., Mazzotta, F., Di Pietro, M., Galli, M., Rusconi, S., Carosi, G., Torti, C., Di Perri, G., Bonora, S., Ensoli, F., and Garaci, E. (2010) Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 5, e13540
23. Guillon, C., Mayol, K., Terrat, C., Compagnon, C., Primard, C., Charles, M. H., Delair, T., Munier, S., and Verrier, B. (2007) Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 25, 7491-7501 (Pubitemid 47516619)
24. Mayol, K., Munier, S., Beck, A., Verrier, B., and Guillon, C. (2007) Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity. Vaccine 25, 6047-6060 (Pubitemid 47082461)
25. Lecoq, A., Moine, G., Bellanger, L., Drevet, P., Thai, R., Lajeunesse, E., Ménez, A., and Léonetti, M. (2008) Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy. Vaccine 26, 2615-2626
26. Liao, W., Chen, Q., Cao, J., Tan, G., Zhu, Z., Zhang, H., Chai, Y., and Pan, W. (2012) A designed Tat immunogen generates enhanced anti-Tat Cterminal antibodies. Vaccine 14, 2453-2461
27. Goldstein, G., Damiano, E., Donikyan, M., Pasha, M., Beckwith, E., and Chicca, J. (2012) HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia. Hum. Vaccin. Immunother. 8, 1425-1430
28. Huet, T., Dazza, M. C., Brun-Vézinet, F., Roelants, G. E., and Wain-Hobson, S. (1989) A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS 3, 707-715 (Pubitemid 20021430)
29. Gregoire, C. J., and Loret, E. P. (1996) Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates. J. Biol. Chem. 271, 22641-22646 (Pubitemid 26304706)
30. Opi, S., Péloponèse, J. M., Jr., Esquieu, D., Campbell, G., de Mareuil, J., Walburger, A., Solomiac, M., Grégoire, C., Bouveret, E., Yirrell, D. L., and Loret, E. P. (2002) Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J. Biol. Chem. 277, 35915-35919
31. Watkins, J. D., Lancelot, S., Campbell, G. R., Esquieu, D., de Mareuil, J., Opi, S., Annappa, S., Salles, J. P., and Loret, E. P. (2006) Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat OYI vaccine. Retrovirology 3, 8
32. Mediouni, S., Watkins, J. D., Pierres, M., Bole, A., Loret, E. P., and Baillat, G. (2012b) A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade. J. Biol. Chem. 287, 11942-11950
33. Steinaa, L., Sørensen, A. M., Nielsen, J. O., and Hansen, J. E. (1994) Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Arch. Virol. 139, 263-271
34. Re, M. C., Furlini, G., Vignoli, M., Ramazzotti, E., Roderigo, G., De Rosa, V., Zauli, G., Lolli, S., Capitani, S., and La Placa, M. (1995) Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10, 408-416
35. Valvatne, H., Szilvay, A. M., and Helland, D. E. (1996) A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation. AIDS Res. Hum. Retroviruses 12, 611-619 (Pubitemid 26120293)
36. Rodman, T. C., Lutton, J. D., Jiang, S., Al-Kouatly, H. B., and Winston, R. (2001) Circulating natural IgM antibodies and their corresponding human cord blood cell-derived MAbs specifically combat the Tat protein of HIV. Exp. Hematol. 29, 1004-1009 (Pubitemid 32725798)
37. Moreau, E., Hoebeke, J., Zagury, D., Muller, S., and Desgranges, C. (2004) Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen. J. Virol. 78, 3792-3796 (Pubitemid 38568316)
38. Manavalan, P., and Johnson, W. C., Jr. (1987) Variable selection method improves the prediction of protein secondary structure from circular dichroism spectra. Anal. Biochem. 167, 76-85
39. Pfeiffer, B., Peduzzi, E., Moehle, K., Zurbriggen, R., Glück, R., Pluschke, G., and Robinson, J. A. (2003) A virosome-mimotope approach to synthetic vaccine design and optimization, synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew Chem. Int. Ed. Engl. 42, 2368-2371 (Pubitemid 36735543)
40. Hardy, F., Djavadi-Ohaniance, L., and Goldberg, M. E. (1997) Measurement of antibody/antigen association rate constants in solution by a method based on the enzyme-linked immunosorbent assay. J. Immunol. Methods 200, 155-159 (Pubitemid 27035697)
41. Bomsel, M., Tudor, D., Drillet, A. S., Alfsen, A., Ganor, Y., Roger, M. G., Mouz, N., Amacker, M., Chalifour, A., Diomede, L., Devillier, G., Cong, Z., Wei, Q., Gao, H., Qin, C., Yang, G. B., Zurbriggen, R., Lopalco, L., and Fleury, S. (2011) Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34, 269-280
42. Reynell, L., and Trkola, A. (2012) HIV vaccines, an attainable goal? Swiss Med Wkly. 142, w13535
43. Feinberg, M. B., and Moore, J. P. (2002) AIDS vaccine models, challenging challenge viruses. Nat. Med. 8, 207-210 (Pubitemid 34250091)
44. Lakhashe, S. K., Velu, V., Sciaranghella, G., Siddappa, N. B., Dipasquale, J. M., Hemashettar, G., Yoon, J. K., Rasmussen, R. A., Yang, F., Lee, S. J., Montefiori, D. C., Novembre, F. J., Villinger, F., Amara, R. R., Kahn, M., Hu, S. L., Li, S., Li, Z., Frankel, F. R., Robert-Guroff, M., Johnson, W. E., Lieberman, J., and Ruprecht, R. M. (2011) Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein, efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29, 5611-5622
45. Bachler, B. C., Humbert, M., Palikuqi, B., Siddappa, N. B., Lakhashe, S. K., Rasmussen, R. A., and Ruprecht, R. M. (2013) Novel biopanning strategy to identify epitopes associated with vaccine protection. J. Virol. 87, 4403-4416